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Abstract
Background: Several high-density oligonucleotide microarray platforms are available for genome-wide single
nucleotide polymorphism (SNP) detection and microarray-based comparative genomic hybridisation (array CGH),
which may be used to detect copy number aberrations in human tumours. As part of the EuroBoNeT network of
excellence for research on bone tumours (eurobonet.eu), we have evaluated four different commercial high-
resolution microarray platforms in order to identify the most appropriate technology for mapping DNA copy
number aberrations in such tumours.
Findings: DNA from two different cytogenetically well-characterized bone sarcoma cell lines, representing a simple
and a complex karyotype, respectively, was tested in duplicate on four high-resolution microarray platforms;
Affymetrix Genome-Wide Human SNP Array 6.0, Agilent Human Genome CGH 244A, Illumina HumanExon510s-duo
and Nimblegen HG18 CGH 385 k WG tiling v1.0. The data was analysed using the platform-specific analysis
software, as well as a platform-independent analysis algorithm. DNA copy number was measured at six specific
chromosomes or chromosomal regions, and compared with the expected ratio based on available cytogenetic
information. All platforms performed well in terms of reproducibility and were able to delimit and score small
amplifications and deletions at similar resolution, but Agilent microarrays showed better linearity and dynamic
range. The platform-specific analysis software provided with each platform identified in general correct copy
numbers, whereas using a platform-independent analysis algorithm, correct copy numbers were determined mainly
for Agilent and Affymetrix microarrays.
Conclusions: All platforms performed reasonably well, but Agilent microarrays showed better dynamic range, and
like Affymetrix microarrays performed well with the platform-independent analysis software, implying more robust
data. Bone tumours like osteosarcomas are heterogeneous tumours with complex karyotypes that may be difficult
to interpret, and it is of importance to be able to well separate the copy number levels and detect copy number
changes in subpopulations. Taking all this into consideration, the Agilent and Affymetrix microarray platforms were
found to be a better choice for mapping DNA copy numbers in bone tumours, the latter having the advantage of
also providing heterozygosity information.
Background
Chromosomal aberrations are frequent in cancer, and
change in gene dosage is a common mechanism for activa-
tion or attenuation of oncogenes and tumour suppressor
genes, respectively. In order to precisely identify chromo-
somal regions of gain and loss, a number of microarray-
based technologies have been developed to measure
genome-wide DNA copy number [1-3]. Microarray-based
comparative genomic hybridisation (array CGH) provides
the means of quantitatively measuring DNA copy number
aberrations at high-resolution and map them directly to
the genome sequence.
High-density oligonucleotide microarrays contain syn-
thetic single-stranded oligonucleotide probes, and differ-
ent designs for array CGH are offered by a number of
companies. The size of the oligonucleotides ranges from
25-mer to 85-mer depending on the type of microarray.
Some of these microarrays have been developed for
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linkage analysis by the identification of single nucleotide
polymorphisms (SNPs), allowing the simultaneous
detection of DNA copy number changes and loss of het-
erozygosity (LOH), which is the regional loss of the con-
tribution to the genome from one parent [4,5]. LOH can
be copy number neutral when the deleted chromosomal
region is compensated by mitotic recombination, result-
ing in homozygosity without physical DNA loss.
With the increasing number of microarray formats
available for detection of DNA copy number changes and
LOH, with differences in design, resolution and experi-
mental information obtainable, there is a need to evaluate
the alternatives in order to identify the best microarray
platform for specific studies. An increasing number of
comparative studies of high-resolution platforms have
been performed [6-15], addressing different types of
research questions. In general, most platforms have been
reported to perform well, but differences occur, and
obviously each platform has its advantages and disadvan-
tages that need to be taken into consideration.
Benign and malignant bone tumours are often found in
bone and show varying degrees of osteogenic, chondro-
genic, fibrogenic or neuroectodermal differentiation,
among others. Primary malignant bone tumours, or bone
sarcomas, arise frequently in the long bones of the extre-
mities [16]. Most tumours arise sporadically, but some
occur in relation to pre-existing conditions of bone or
inherited diseases. Bone sarcomas can occur at any age,
but the tumours frequently occur in children and adoles-
cents in addition to older people. About 35% of the bone
sarcomas are osteosarcomas, 25% are chondrosarcomas
and 16% are Ewing sarcomas/PNET (Primitive NeuroEc-
todermal Tumour) [16]. Most conventional osteosarco-
mas have complex karyotypes with numerous numerical
and structural aberrations, whereas the karyotype com-
plexity is in general reduced from chondrosarcomas to
Ewing sarcoma/PNET [16]. Both high level of amplifica-
tion and homozygous deletion of various sizes can occur
in these tumour types. Due to their complex karyotype,
microarray-based technologies are particularly useful to
decipher chromosome aberrations in these tumours.
As part of the EuroBoNeT European network of excel-
lence for research on bone tumours (European Network
to Promote Research into Uncommon Cancers in Adults
and Children: Pathology, Biology and Genetics of Bone
Tumours, eurobonet.eu), we have evaluated four differ-
ent high-resolution commercial microarray platforms for
DNA copy number analysis; Affymetrix Genome-Wide
Human SNP Array 6.0, Agilent Human Genome CGH
244A, Illumina HumanExon510s-duo and Nimblegen
HG18 CGH 385 k WG tiling v1.0, in order to identify
the most appropriate microarray platform for mapping
DNA copy number aberrations in bone tumours.
Materials and methods
Test material
Two different cell lines were selected for the testing;
TC-32, an Ewing sarcoma/PNET cell line with simple
chromosomal aberrations, and OSA (termed SJSA-1 by
ATCC), a conventional osteosarcoma cell line with com-
plex genomic rearrangements. The TC-32 cell line was
kindly provided by Dr. S.A. Burchill (St. James’ Univer-
sity Hospital, Leeds, UK), and the SJSA-1 (OSA) cell
line was obtained from ATCC.
TC-32 was cultured in RPMI 1640 GlutaMAX medium
supplemented with 20% foetal calf serum and penicillin/
streptomycin (all Invitrogen, Carlsbad, CA, USA). OSA
was grown in RPMI1640 (Lonza, Basel, Switzerland) sup-
plemented with 10% foetal calf serum (PAA Laboratories
GmbH, Pasching, Austria), GlutaMAX (Invitrogen) and
penicillin/streptomycin (Lonza), at 37°C with 5% CO2.
All cells were split when reaching 80% confluency.
DNA was isolated from each cell line using the High
Pure PCR Template Isolation Kit (Roche, Basel, Switzer-
land) following the manufacturer’s instructions. For two
channel arrays (Agilent and Nimblegen), a commercial
pooled male DNA was used as a reference (Promega,
Madison, WI, USA), while for single channel arrays
(Affymetrix and Illumina), data from a normal sample set
provided by each supplier was used as a normal reference
control. The same DNA preparations from the cell lines,
reference DNA and Human Cot-1 DNA (Invitrogen)
were used for all platforms and replicates in order to
avoid effects of DNA quality or cell line variability on the
results.
Microarray platforms
The cell lines were profiled for DNA copy number
changes in duplicate using four different high-resolution
oligonucleotide microarray platforms; Affymetrix
Genome-Wide Human SNP Array 6.0, Agilent Human
Genome CGH 244A, Illumina HumanExon510s-duo
and Nimblegen HG18 CGH 385 k WG Tiling v1.0.
Information and characteristics for each platform are
summarized in Table 1. Hybridisations for Affymetrix
and Nimblegen microarrays were carried out at the
Microarray Core Facility at The Norwegian Radium
Hospital (Oslo, Norway), whereas hybridisations for Agi-
lent and Illumina microarrays were performed at Service
XS (Leiden, The Netherlands). For all platforms, the
suppliers’ protocols were strictly followed. All datasets
can be viewed in the microarray depository ArrayEx-
press (http://www.ebi.ac.uk/microarray-as/ae/, accession
number E-TABM-805).
Affymetrix Genome-Wide Human SNP Array 6.0
The Affymetrix Genome-Wide Human SNP Array 6.0
contains more than 1.8 million genetic markers, including
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more than 906,000 SNP probes and more than 946,000
probes designed for detection of DNA copy number
changes. Quality control and normalization were per-
formed in Genotyping Console v3.0.1 (Affymetrix). Data
was quality controlled using the contrast quality control
(CQC) algorithm with a minimal call rate of > 86%. DNA
copy number analysis was performed in Genotyping Con-
sole using quantile probe level normalization, regional GC
correction and default settings. Segmentation was per-
formed using an HMM algorithm, and segments were
reported as copy number states (i.e. 0, 1, 2, 3 and ≥4
copies).
Agilent Human Genome CGH 244A
The Agilent Human Genome CGH 244A microarray
contains approximately 236,000 in situ synthesized
60-mer oligonucleotides spanning coding and non-
coding regions. Microarray images were processed in
Agilent Feature Extraction v9.1 using default settings
(no background subtraction and spatial detrend), as well
as “ranked consistent probe methods” for normalization.
Export files were further analysed using Agilent DNA
Analytics v4.0.76. Aberrations were detected using the
AMD-2 algorithm with a threshold of 8.0, and a filter
against aberrations with less than six probes was used.
Illumina HumanExon510s-duo
The HumanExon510s-duo microarray is a gene centric
array, having the majority of the 511,354 contained mar-
kers within or near genes. More than 60% of the mar-
kers are located within 10 kb of a gene, and the probes
provide coverage for 99.9% of the RefSeq genes. In addi-
tion, probes for known regions of copy number variation
are included. Fluorescent intensities from the scanner
were imported into BeadStudio v3.3.4 (Illumina) and
normalized using quantile normalization. DNA copy
number analysis was performed using the cnvPartition
algorithm v1.2.0 and default settings.
Nimblegen HG18 CGH 385 k WG Tiling v1.0
The Nimblegen HG18 CGH 385 k WG Tiling v1.0
microarray contains 385,000 long oligonucleotides
(50-75-mer) that tile the human genome. Microarray
images were processed in NimbleScan v2.3 (Nimblegen),
and segmentation was performed using the DNACopy
algorithm with default settings.
Platform-independent analysis
Platform-independent analysis was performed in Nexus
(BioDiscovery, El Segundo, CA, USA) using the rank
segmentation algorithm with default settings (threshold
of 0.6 for high gain, 0.2 for gain, -0.2 for loss and -1.0
for big loss). SNP analysis of the Affymetrix and Illu-
mina data was performed in Nexus using the SNP-
FASST segmentation algorithm with default settings.
Results and discussion
Four different commercial high-resolution oligonucleo-
tide microarray platforms, Affymetrix Genome-Wide
Human SNP Array 6.0, Agilent Human Genome CGH
244A, Illumina HumanExon510s-duo and Nimblegen
HG18 CGH 385 k WG tiling v1.0, were evaluated for
genomic profiling of bone tumours. Information and
characteristics for each platform are summarized in
Table 1. Two different bone sarcoma cell lines, TC-32
(Ewing sarcoma/PNET) and OSA (conventional osteo-
sarcoma), having simple and extensive chromosomal
aberrations, respectively, were selected for the testing.
Multicolour COBRA-FISH-based karyotyping of the TC-
32 cell line has been described earlier [17,18], with the
resulting karyotype 48, XX,+i(1)(q10),+8, t(11;22)(q24;
q12).
DNA from the cell lines was labelled and hybridised in
duplicate to all four microarray types following the man-
ufacturers’ instructions, and the same DNA preparations
were used for all platforms and replicates in order to
avoid effects of DNA quality or cell line variability on
the results. Data processing and analysis were performed
using the corresponding software for each of the plat-
forms with default settings.
Reproducibility
To measure the reproducibility of log2 ratios between
replicate hybridisations, Pearson’s correlation was calcu-
lated based on all data points (Table 2). Illumina micro-
arrays showed the highest degree of correlation between
Table 1 Microarray platform characteristics
Platform Technology Sample
labelling
Sample
requirement
Number of
features
Median probe
spacing
Analysis
Affymetrix Genome-Wide Human
SNP Array 6.0
Oligonucleotide
(25 nt)
PCR
reduction
0.5 μg 1,852 k < 700 bp DNA copy number
and LOH
Agilent Human Genome CGH
244A
Oligonucleotide
(60 nt)
Whole
genome
0.5-1 μg 236 k 8,900 bp DNA copy number
Illumina HumanExon510s-duo Oligonucleotide
(25 nt)
PCR
reduction
0.75 μg 511 k 3,200 bp DNA copy number
and LOH
Nimblegen HG18 CGH 385 k WG
Tiling v1.0
Oligonucleotide
(50-75 nt)
Whole
genome
1 μg 385 k 6,270 bp DNA copy number
Characteristics of the different high-resolution microarray platforms evaluated.
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replicates, 0.96 and 0.94 for TC-32 and OSA, respec-
tively. Agilent microarrays showed also a high correla-
tion between replicates, 0.91 for both cell lines, while
Affymetrix microarrays showed an intermediate correla-
tion of 0.75 and 0.84 for TC-32 and OSA, respectively.
Nimblegen microarrays showed the lowest correlation,
0.73 and 0.63 for OSA and TC-32, respectively.
Although having a more complex karyotype, the OSA
cell line showed slightly better correlation for the repli-
cates than the TC-32 cell line for Affymetrix and Nim-
blegen microarrays. Scatter plots of log2 ratios for the
replicate hybridisations for all microarray platforms are
shown in Additional file 1.
In a previous study of melanoma cell lines using lower
resolution oligonucleotide microarrays from Affymetrix,
Agilent and Nimblegen, similar results were observed [8].
Here, the highest resolution array from Agilent tested (185
K) showed the highest correlations (ranging 0.72-0.86 for
the different samples hybridised), whereas the highest
resolution array from Affymetrix tested (500 K) showed
intermediate correlations (0.54-0.67). Also here the Nim-
blegen array (1500 K) showed the lowest correlations
(0.27-0.57). In addition, a significant higher degree of cor-
relation was observed for the higher-density microarrays
compared to the lower-density microarrays from the same
supplier (Agilent 185 K vs 44 K and Affymetrix 500 K vs
100 K) [8]. Although not directly comparable, this is in
concordance with the even higher correlations between
replicate hybridisations observed with the higher-resolu-
tion microarrays from Agilent and Affymetrix used here.
Similar results have also been observed between repli-
cate hybridisations of Affymetrix 500 K arrays, Agilent
44B arrays and Illumina Hap550 arrays for one leukae-
mia cell line [14]. The standard deviation for each probe
across four replicate hybridisations was calculated, and
Illumina arrays showed the lowest median standard
deviation (0.059), followed by Agilent (0.083) and Affy-
metrix (0.101). However, when the median standard
deviation was normalized to the number of measure-
ments on each platform, all platforms showed similar
levels of variation [14].
Signal response to copy number
To quantify and evaluate the signal response to copy
number for each platform, the measured DNA copy
numbers for five specific chromosomes or chromosomal
regions in TC-32 (representing 0, 1, 2, 3 and 4 copies)
and one specific chromosomal region in OSA (repre-
senting high-level amplification) were compared with
the expected ratios based on available cytogenetic and
molecular information. Homozygous deletion of the
locus around the tumour suppressor gene CDKN2A in
9p21.3, heterozygous deletion of 9p21.3-p21.2, normal
copy number of chromosome 2, three copies of
Table 2 Reproducibility of replicate hybridisations and signal response to copy number
Platform Corr TC-
32
Corr
OSA
0n: CDKN2A
TC-32
1n: 9p21.3-
p21.2
TC-32
Log2ratio
(SD)
2n: Chr 2
TC-32
Log2ratio
(SD)
3n: Chr 8
TC-32
Log2ratio
(SD)
4n: 1q
TC-32
Log2ratio
(SD)
>10n: MDM2
OSA
Log2ratio
(SD)
Size
[kb]
Log2ratio
(SD)
Size
[kb]
Theoretical value 1.0 1.0 < -3 - -1.0 0.0 0.58 1.0 > 3 -
Affymetrix Genome-
Wide
Human SNP Array
6.0
0.75 0.84 -1.79 (0.93) 166 -0.53 (0.43) 0.00 (0.41) 0.34 (0.44) 0.56 (0.44) 1.86 (0.49) 146
-2.09 (0.92) 148 -0.62 (0.35) 0.00 (0.32) 0.37 (0.34) 0.59 (0.34) 1.99 (0.50) 146
Agilent Human
Genome CGH 244A
0.91 0.91 -4.72 (1.57) 135 -0.96 (0.31) 0.00 (0.19) 0.52 (0.27) 0.92 (0.22) 4.69 (0.24) 147
-4.83 (1.53) 135 -0.97 (0.30) 0.01 (0.21) 0.54 (0.29) 0.95 (0.25) 4.74 (0.21) 147
Illumina Human
Exon510 s-duo
0.96 0.94 -4.72 (1.07) 171 -0.67 (0.54) -0.05 (0.20) 0.22 (0.29) 0.36 (0.26) 1.24 (0.59) 122
-4.69 (0.91) 171 -0.67 (0.59) -0.05 (0.20) 0.22 (0.29) 0.36 (0.26) 1.23 (0.58) 122
Nimblegen HG18
CGH
385 k WG Tiling
v1.0
0.63 0.73 -0.85 (0.57) 169 -0.45 (0.30) -0.06 (0.19) 0.24 (0.21) 0.48 (0.24) 2.58 (0.98) 156
-0.88 (0.50) 169 -0.47 (0.29) -0.06 (0.20) 0.26 (0.21) 0.53 (0.23) 2.46 (1.0) 156
Pearson’s correlation of log2 ratios for the replicate hybridisations based on all data points and the average log2 ratio with standard deviation for six specific
chromosomes or chromosomal regions, representing 0, 1, 2, 3 and 4 copies in TC-32, as well as high-level amplification in OSA, for each hybridisation. In
addition, the measured size of the regions for homozygous deletion of the CDKN2A locus in TC-32 and high-level amplification of the MDM2 locus in OSA is
given for each hybridisation.
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chromosome 8 and four copies of the long arm of chro-
mosome 1 were measured in TC-32, and high-level
amplification of the locus around the oncogene MDM2
in 12q15 was measured in OSA. For both replicate
hybridisations, the average log2 ratio was determined for
each normalized segment, as well as the standard devia-
tion of the signals, and this is presented in Table 2.
Figure 1 shows a plot of the measured average log2
ratios compared to the theoretical values. In addition,
the size of the homozygous deletion of the CDKN2A
locus in TC-32 and the high-level amplification of the
MDM2 locus in OSA were estimated (Table 2). Copy
number plots of the homozygous deletion of the
CDKN2A locus as well as the heterozygous deletion of
9p21.3-p21.2 in TC-32 are shown in Additional file 2
for all microarray platforms.
The values were in general similar between the repli-
cate hybridisations for all platforms and regions. Agi-
lent arrays showed the highest dynamic range, from
average log2 ratio of -4.78 to 4.72 for the homozygous
deletion of the CDKN2A locus and the high-level
amplification of the MDM2 locus, respectively, and
gave almost expected log2 ratios for all regions, close
to the theoretical values (Table 2). Affymetrix results
were second best for log2 ratios for regions of
increased copy number, 3 and 4 copies, but not so
good on regions of decreased copy number, 0 and 1
copies. The Illumina results deviated most from the
expected log2 ratios for 3 and 4 copies (theoretical
value 0.58 and 1.0, respectively), giving on average log2
ratios of 0.22 and 0.36, respectively, while the Nimble-
gen data deviated most for 0 and 1 copies (theoretical
value <-1 and -1.0, respectively), giving on average log2
ratios of -0.87 and -0.46, respectively. For the high-
level amplification of the MDM2 locus in OSA,
expected to have a log2 ratio well above 3 based on
previous results [19,20], Nimblegen arrays gave the
second best values, average log2 ratio of 2.52, whereas
Affymetrix and Illumina arrays gave average log2 ratios
of 1.93 and 1.24, respectively.
A regression line was calculated for the measured
average log2 ratios of the regions representing 1, 2, 3
and 4 copies, and the slope and R2 values are given in
Figure 1. The regions representing 0 and > 10 copies
were omitted from the regression line, since the
expected log2 ratio for the homozygous deletion is not
an exact number (< -3) and the exact log2 ratio for the
high-level amplification is unknown (> 3). All platforms
showed a high linearity of the measured log2 ratios, but
the slope of the regression line varied. The slope of the
measurements for the Agilent arrays was closest to the
theoretical value, followed by Affymetrix and Illumina
arrays, whereas the measurements from the Nimblegen
arrays deviated most.
In a previous study using lower resolution oligonu-
cleotide microarrays from Affymetrix (250 K), Agilent
(185 K) and Illumina (317 K), as well as BAC arrays
(32 K), for screening chronic lymphocytic leukaemia,
similar results were observed [9]. Agilent 185 K arrays
and 32 K BAC arrays showed the highest dynamic
range, where the Agilent arrays showed the most correct
response to loss of one copy and gain of one copy,
whereas the BAC arrays showed the most correct
response to homozygous deletion. A notable difference
in the scale of log2 ratios has also previously been
observed between Agilent 44 K arrays, Illumina 109 K
arrays and ROMA/Nimblegen 82 K arrays for screening
breast cancer, with higher signals for the Agilent arrays
[6]. Affymetrix 100 K and 250 K arrays also showed
higher mean log2 ratio of chromosome X than Nimble-
gen 385 K arrays in sex-mismatched hybridisations of
patients with submicroscopic genomic copy number var-
iations [11]. In a previous study on melanoma cell lines,
Agilent 185 K arrays showed the highest signals for 4
copies (average log2 ratio 0.86) as well as the highest
signal to noise ratio, whereas Affymetrix 500 K arrays
showed intermediate values (average 0.55) and Nimble-
gen 1500 K arrays showed the lowest values (average
0.37) [8].
Concerning the variation in log2 ratios within a chro-
mosome or chromosomal region, Affymetrix arrays
showed the highest standard deviation for the regions
Figure 1 Plot of measured log2 ratios compared to theoretical
values for specific chromosomes or chromosomal regions. Plot
of average measured log2 ratios compared to theoretical values for
six specific chromosomes or chromosomal regions; the CDKN2A
locus in 9p21.3, 9p21.3-p21.2, chromosome 2, chromosome 8, 1q (all
in TC-32) and the MDM2 locus in 12q15 (in OSA) (representing 0, 1,
2, 3, 4 and >10 copies, respectively) for all microarray platforms and
replicates. The slope and regression coefficient (R2) for the
regression line based on four of the regions, representing 1, 2, 3
and 4 copies, are given.
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representing 2, 3 and 4 copies, whereas the other plat-
forms showed equal variation. Illumina and Agilent arrays
showed the highest standard deviation for the regions
representing 1 and 0 copies, respectively (0.57 and 1.55).
Nimblegen arrays showed the lowest standard deviations
for the regions of loss, but this is most likely due to com-
pression of the log2 ratios since the Nimblegen data
deviated most for 0 and 1 copies. For the high-level
amplification of the MDM2 locus, Agilent showed the
lowest and Nimblegen the highest standard deviations
(0.23 and 0.99, respectively).
The baseline variation has also been determined in
previous studies. For the screening of chronic lympho-
cytic leukaemia, Affymetrix 250 K arrays, Agilent
185 K arrays and Illumina 317 K arrays showed similar
average log2 ratio and standard deviation of a region
with normal copy number (chromosome 1) [9]. How-
ever, when assessing the baseline variation in form of
autocorrelation of the whole genome, Agilent showed
the lowest variation, followed by Affymetrix and Illu-
mina. For the previous study of patients with submi-
croscopic genomic copy number variations, Nimblegen
185 K arrays showed a higher standard deviation of
the log2 ratios of the whole genome (excluding regions
harbouring the variations) than the Affymetrix 250 K
and 100 K arrays [11].
The distribution of log2 ratios of all probes within the
six specific chromosomes or chromosomal regions
(representing 0, 1, 2, 3, 4 and >10 copies, respectively)
for one hybridisation from all microarray platforms is
shown in Figure 2. The replicate hybridisation showed a
similar pattern (data not shown). The distribution is
shown for both the normalized data and a smoothed
version of the same data. The data were smoothed using
Gaussian smoothing with a window size of 50 kb and
standard deviation of 10 kb, in order to reduce the var-
iation. Smoothing was not possible for the small regions
representing 0 and >10 copies (the CDKN2A and
MDM2 loci) due to insufficient number of probes. For
the normalized data, the curves for the different copy
number levels were by far best separated by the Agilent
data, whereas the curves were highly overlapping for the
Affymetrix data. However, smoothing of the data had a
huge effect on the Affymetrix data, narrowing the distri-
butions of the log2 ratios and thus better separating the
curves. The smoothing also further improved the Agi-
lent, Illumina and Nimblegen data, but to a smaller
extent. The most difficult separation for all platforms
was to distinguish between 3 and 4 copies, and this was
particularly not easy with the Illumina data where the
two curves were highly overlapping.
Similar results were observed in a previous study of
melanoma cell lines, with the distribution of log2 ratios
of regions of 2 and 4 copies [8]. The distribution was
best separated for the Agilent 185 K and 44 K arrays,
whereas the Affymetrix 500 K and 100 K arrays showed
intermediate results. For the Nimblegen 1500 K arrays,
the distribution of log2 ratios of regions of 2 and 4
copies was indistinguishable. However, in line with the
observations in this study, smoothing of the data
improved the results for all platforms, with a most pro-
found effect for the Nimblegen 1500 K arrays and Affy-
metrix 100 K arrays, the two lowest ranking in terms of
signal to noise ratios [8].
The size of the small aberrations of CDKN2A and
MDM2 was estimated manually, and this revealed very
similar results for all microarray platforms (Table 2).
Only Affymetrix arrays showed a difference in size of
the deletion of the CDKN2A locus between the replicate
hybridisations for TC-32, detected to be 166 and
148 kb, respectively.
Detection of DNA copy number aberrations
The aberrant regions examined for signal response to
copy number were scored using the analysis software
provided for each microarray platform with default set-
tings. In addition, data from all platforms were exported
into Nexus (BioDiscovery) in order to make an indepen-
dent scoring of the aberrations. This software also has
advantages when it comes to downstream integration
with other genome-level data. In Nexus, all four plat-
forms were analysed using the rank segmentation algo-
rithm with default settings. Table 3 shows the scoring of
the aberrant regions examined for signal response to
copy number from the platform-specific analysis soft-
ware as well as Nexus for one hybridisation from all
platforms. The replicate hybridisation showed a similar
pattern (data not shown). Detection of the homozygous
deletion of the CDKN2A locus as well as the heterozy-
gous deletion of 9p21.3-p21.2 in TC-32 using Nexus for
all platforms is shown in Additional file 3.
Using the platform-specific analysis software, Affymetrix,
Agilent and Illumina scored the correct copy number
level for all regions representing 0, 1, 2, 3 and 4 copies
in TC-32, and indicated the high-level amplification in
OSA. The only exception was the scoring of 4 copies of
1q using the Illumina data, where the software segmen-
ted the region into segments of mainly 3 copies and
some smaller segments of 4 copies. For Nimblegen, the
corresponding analysis software segments the data and
displays them, without giving copy number scores.
Using the platform-independent Nexus software, all
regions were determined to have the correct copy num-
ber for the Affymetrix data (Table 3). The region of 1
copy was over-scored as a homozygous deletion for
Agilent, because of the low log2 ratios of this segment
(average -0.97) and the threshold for homozygous dele-
tion in Nexus (default log2 ratio < -1.0). The region of 4
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Figure 2 Distribution of log2 ratios for specific chromosomes or chromosomal regions. Distribution of log2 ratios of all probes within six
specific chromosomes or chromosomal regions; the CDKN2A locus in 9p21.3, 9p21.3-p21.2, chromosome 2, chromosome 8, 1q (all in TC-32) and
the MDM2 locus in 12q15 (in OSA) (representing 0, 1, 2, 3, 4 and >10 copies, respectively) for all microarray platforms for A) normalized data and
B) normalized data that have been smoothed using Gaussian smoothing with a window size of 50 kb and standard deviation of 10 kb.
Smoothing was not possible for the small regions representing 0 and >10 copies (the CDKN2A and MDM2 loci) due to insufficient number of
probes.
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copies was scored as one copy less for Illumina, most
likely due to compression of the log2 values. For the
Nimblegen data, Nexus detected the homozygous dele-
tion as 1 copy and the 1q region as 3 copies instead of
4, most likely also due to compression of the log2 values.
In a previous study, Affymetrix 500 K arrays, Agilent
244 K arrays and Nimblegen 385 K arrays were com-
pared for detection of submicroscopic constitutional
aberrations [15]. In that study, using the corresponding
analysis program, all 10 previously known abnormalities
investigated were detected using the Agilent data,
whereas one and three aberrations were not identified
using the Affymetrix and Nimblegen data, respectively.
However, using the software dChip in combination with
an R script, all aberrations were detected using the Affy-
metrix data as well [15]. For the comparison of Affyme-
trix 500 K arrays, Agilent 44B arrays and Illumina
Hap550 arrays, all known alterations in a leukaemia cell
line were identified using both a platform-specific soft-
ware and a platform-independent analysis (circular bin-
ary segmentation) [14].
The number of overall copy number aberrations in
chromosome 1-22 detected by Nexus is given in Table 4,
for both TC-32 and OSA for all microarray platforms
and both replicate hybridisations. Detection of the copy
number aberrations is given in Additional File 4. Nexus
divides the copy number aberrations in four categories;
homozygous copy loss, loss, gain and high copy gain
depending on the log2 ratio of the segments. The number
of detected copy number aberrations was in general simi-
lar between the replicate hybridisations, except for the
categories gain and loss in TC-32 by Affymetrix, where
the replicates varied with 31 and 36 aberrations,
respectively.
The number of detected aberrations varied between the
platforms, in general showing that microarrays with a
higher number of probes detect more segments of copy
number aberrations. Affymetrix showed by far the high-
est number of aberrations, as expected with the 1.8 mil-
lion probes on the array, and most additional aberrations
compared to the other platforms were small regions
(Table 4 and Additional File 4). However, Agilent, with
only 236 k probes on the array, also showed a high num-
ber of small aberrations in the OSA cell line. Illumina
identified approximately the same number of total aber-
rations as Agilent, whereas Nimblegen identified consid-
erably less than the other platforms (Table 4). Some
differences between the platforms were observed for lar-
ger regions, for instance the heterozygous deletion of 4q
in OSA detected by Agilent, which was partly detected by
Table 3 Detection of copy number of specific regions
Platform 0n: CDKN2A
TC-32
1n: 9p21.3-p21.2
TC-32
3n: Chr 8
TC-32
4n: 1q
TC-32
>10n: MDM2
OSA
Platform Nexus Platform Nexus Platform Nexus Platform Nexus Platform Nexus
Affymetrix Genome-Wide Human SNP array 6.0 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Agilent Human Genome CGH 244A Yes Yes Yes 0n Yes Yes Yes Yes Yes Yes
Illumina HumanExon510s-duo Yes Yes Yes Yes Yes Yes 3n/4n 3n Yes Yes
Nimblegen HG18 CGH 385 k WG Tiling v1.01 - 1n - Yes - Yes - 3n - Yes
1Nimblegen’s analysis software segments the data without scoring of copy number
Detection of copy number of five specific chromosomes or chromosomal regions representing 0, 1, 3 and 4 copies in TC-32, as well as high-level amplification in
OSA, using the platform-specific software and the platform-independent software Nexus.
Table 4 Detection of copy number aberrations
Platform TC-32 OSA
Homozygous
copy loss
Loss Gain High copy gain Homozygous
copy loss
Loss Gain High copy
gain
Affymetrix Genome-Wide Human SNP array 6.0 19 45 40 21 18 100 101 72
23 76 76 28 16 114 123 82
Agilent Human Genome CGH 244A 4 11 10 2 9 82 58 42
4 8 10 2 13 103 65 37
Illumina HumanExon510s-duo 3 32 21 3 2 75 77 33
3 33 19 2 4 86 78 36
Nimblegen HG18 CGH 385 k
WG Tiling v1.0
0 7 15 2 1 31 62 36
0 11 6 0 1 25 55 36
Number of copy number aberrations detected in chromosome 1-22 in TC-32 and OSA using the platform-independent software Nexus.
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Illumina and not at all by Nimblegen. Affymetrix
detected several small regions within 4q as deletions
(Additional File 4).
Similar results were observed in the analysis of the total
number of chromosome segments altered in a leukaemia
cell line, where the highest resolution arrays (Illumina
Hap550) showed the highest number of identified seg-
ments, followed by Affymetrix 500 K arrays and Agilent
44B arrays [14]. On the other hand, for the screening of
chronic lymphocytic leukaemia, the lowest resolution
array (Agilent 185 K) detected the highest number of
platform-specific copy number aberrations, followed by
Affymetrix 250 K arrays and Illumina 317 K arrays [9].
Most of these aberrations were smaller segments. For the
aberrations detected in common by two of the platforms,
most often the Affymetrix and Agilent platforms showed
concordant results [9]. A comparison of copy number
aberrations detected in 18 melanoma cell lines by Affy-
metrix 500 K arrays and Agilent 244 K arrays showed a
similar number of total aberrations detected with a 29%
overlap between the two platforms [8].
Scoring of loss of heterozygosity
An advantage of the Affymetrix and Illumina platforms
is that they also provide global polymorphism informa-
tion, and thus can indicate regions of LOH that could
be involved in loss-of-function mutations, haploinsuffi-
ciency, etc. SNP analysis of the Affymetrix and Illumina
data was performed in Nexus using the SNP-FASST
segmentation algorithm with default settings.
In general, Affymetrix detected slightly more regions
of allelic changes overall for both samples, but both
platforms detected allelic changes in the regions with
copy number aberrations scored by Nexus. In addition,
regions of copy number-neutral allelic changes were
identified, and detection of the copy number-neutral
LOH of 1q in OSA using Nexus is shown in Addi-
tional file 5. Nexus divides the detection of allelic
changes in two categories; LOH and allelic imbalance,
depending on the distribution of the allelic ratio plot.
For the copy-number neutral LOH of 1q in OSA, as
well as other similar regions, the allelic changes were
scored as LOH for the Illumina data, whereas the alle-
lic changes were only scored as allelic imbalance for
the Affymetrix data, due to a less defined distribution
of the allelic ratio plot. The allelic ratios of the Illu-
mina SNP data were overall better separated and thus
more precisely scored, but all the allelic changes iden-
tified using the Illumina data were also identified using
the Affymetrix data. Thus, the two platforms both per-
form well in detecting regions of allelic imbalance
based on the SNP data.
Detection of LOH has previously been compared for
Affymetrix 250 K arrays and Illumina 317 K arrays for
chronic lymphocytic leukaemia [9]. Most loci were con-
cordant between the two platforms, especially for
regions > 4 Mb, but more differences were observed for
smaller regions. The Illumina arrays showed in general a
higher detection rate, in contrast with this study, but
also a lower noise level in the LOH analysis, which was
also observed in this study.
Conclusions
All microarray platforms performed well in terms of
reproducibility, delimiting small amplifications and dele-
tions, as well as scoring the aberrations. Agilent microar-
rays showed better linearity and dynamic range since the
measured log2 ratios using these platforms were closer to
the expected ratios. The platform-specific analysis soft-
ware identified in general correct copy numbers, whereas
using a platform-independent analysis algorithm, correct
copy numbers were determined mainly for Agilent and
Affymetrix microarrays, implying more robust data. Bone
tumours like osteosarcomas are heterogeneous tumours
with complex karyotypes that may be difficult to inter-
pret, and it is of importance to be able to well separate
the copy number levels and detect copy number changes
in subpopulations. Less complex tumours will also bene-
fit from an increased linearity and dynamic range by
allowing reliable detection of small subpopulations of
cells with DNA copy number changes within relatively
homogenous tumours. Taking all this into consideration,
the Agilent and Affymetrix microarray platforms were
found to be a better choice for mapping DNA copy num-
bers in bone tumours, the latter having the advantage of
also providing heterozygosity information.
Additional material
Additional file 1: Scatter plot of log2 ratios and the correlation
coefficient for the replicate hybridisations of TC-32 and OSA for all
microarray platforms.
Additional file 2: Copy number plot of the homozygous deletion of
the CDKN2A locus and the heterozygous deletion of 9p21.3-p21.2
in TC-32 for all microarray platforms.
Additional file 3: Detection of the homozygous deletion of the
CDKN2A locus and the heterozygous deletion of 9p21.3-p21.2 in
TC-32 using Nexus for all microarray platforms.
Additional file 4: Detection of copy number aberrations in
chromosome 1-22 in TC-32 and OSA using Nexus for all microarray
platforms.
Additional file 5: Detection of the copy number-neutral LOH of 1q
in OSA using Nexus for the Affymetrix and Illumina platforms.
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